

Table of Contents

| CONTENTS | PAGE NO |
|---|----------------|
| CHAPTER 1 | 1 |
| INTRODUCTION AND REVIEW OF LITERATURE ON PROTEIN FOLDING, AMYLOIDOSIS AND NEURODEGENERATION* | 1 |
| Abstract | 1 |
| 1.1 Introduction to Protein Folding | 2 |
| 1.2- History and clinical relevance of amyloidosis | 3 |
| 1.3- Intermediate Pathways in Protein aggregation | 4 |
| 1.4- Cellular mechanisms against protein misfolding | 7 |
| 1.5- Amyloids and associated diseased conditions | 8 |
| 1.6 Amyloid formation mechanism | 12 |
| (A) From Amyloid Precursor Protein to Amyloid β - sheet formation: | 12 |
| (B) Formation of amyloids <i>in vitro</i> : | 13 |
| 1.7- Structural characteristics of amyloids | 16 |
| 1.8- Factors modulating the amyloid formation | 19 |
| (A) Hydrophobicity and secondary structure: | 19 |
| (B) Sequence of Amino Acids: | 20 |
| (C) Unfolded areas in the protein | 21 |
| 1.9- Nucleotide imbalance and neurodegeneration | 21 |
| (A) Purinergic Signaling | 25 |
| (B) Nucleosides, Nucleotides and Neurodegenerative diseases | 25 |
| Adenosine | 26 |
| Adenosine Triphosphate (ATP) | 26 |
| Guanine-based purines (GBPs) | 27 |
| (C) Pyrimidines and Neurodegeneration: | 28 |
| (D) Drug development against amyloid diseases: Current and future strategies | 29 |
| 1.10- Model Proteins used in this study | 34 |
| Hen Egg White Lysozyme (HEWL) | 34 |
| 1.11- Scope and Objectives of the current study | 35 |
| CHAPTER 2 | 37 |
| INTERACTION OF SELECTED BIOMOLECULES AND METABOLITES WITH AMYLOIDOGENIC PROTEINS* | 37 |

| | |
|--|-----------|
| Abstract | 37 |
| 2.1: Introduction | 38 |
| 2.2 Methodology | 39 |
| 2.2.1 Preparation of model proteins: | 39 |
| 2.2.2 Preparation of Ligands | 40 |
| 2.2.3 ADME analysis of ligands | 40 |
| 2.2.4 Molecular Docking using Autodock Tools | 41 |
| 2.2.5 Visualisation and analyses | 41 |
| 3.0 Results | 42 |
| 3.1 Docking analysis with hen egg-white lysozyme | 42 |
| 3.2 Docking analysis with Amyloid β peptides | 49 |
| 3.3 SWISS ADME analysis of molecules | 53 |
| 4.0 Discussion and Conclusion | 54 |
| CHAPTER 3 | 55 |
| Nucleosides and Nitrogenous Bases Inhibit Protein Amyloidosis: A Biophysical and Computational Analysis Using Hen Egg White Lysozyme as Model System* | 55 |
| Abstract | 55 |
| 3.1. Introduction | 56 |
| 3.2. Materials and Methods | 57 |
| 3.2.1 Materials | 57 |
| 3.2.2 Methods | 57 |
| 3.2.2.1 Buffer, Protein and metabolites solutions | 57 |
| 3.2.2.2 Hen Egg White Lysozyme Amyloid formation | 58 |
| 3.2.2.3 Thioflavin T assay | 58 |
| 3.2.2.3 ANS Assay | 59 |
| 3.2.2.4 Aggregation Index measurements | 59 |
| 3.2.2.5 Dynamic Light Scattering | 59 |
| 3.2.2.6 Atomic Force Microscopy (AFM) | 59 |
| 3.2.2.8 Molecular Dynamics and Simulation | 60 |
| 3.2.2.9 Statistical analyses using OriginPro (Learning Edition) | 61 |
| 3.3 Results | 61 |
| 3.3.1 HEWL aggregates have a higher growth rate in near physiological pH than pH 12.2 | 61 |
| 3.3.2 ThT and ANS assay at near physiological pH | 63 |
| 3.3.3 Aggregation index at near physiological pH | 64 |
| 3.3.4 ThT and ANS assay at pH 12.2 | 64 |
| 3.3.5 Aggregation index at pH 12.2 | 66 |
| 3.3.6 Dynamic Light Scattering Study (DLS) | 66 |

| | |
|--|------------|
| 3.3.7 AFM imaging of HEWL oligomers /amyloids | 70 |
| 3.3.8 Aggregation prone regions and pH-dependent disorder | 70 |
| 3.3.9 Molecular Dynamics and Simulation | 72 |
| 3.3.9.1 RMSD, RMSF and Radius of Gyration analyses | 72 |
| 3.3.9.2 SASA, DSSP and hydrogen bond analyses | 73 |
| 3.3.9.3 MM/PBSA energy analyses | 75 |
| 3.4. Discussion | 78 |
| 3.5 Concluding remarks | 82 |
| Chapter 4 | 84 |
| Investigating Potential Mechanisms of Selected Intracellular Metabolites on Preformed Lysozyme Oligomers at Physiological pH* | 84 |
| Abstract | 84 |
| 4.1 Introduction | 85 |
| 4.2 Materials and Methods | 86 |
| 4.2.1 Materials | 86 |
| 4.2.2 Preparation of stock solutions | 87 |
| 4.2.3 Generation of HEWL oligomers | 87 |
| 4.2.4 Tryptophan fluorescence and fluorescence quenching | 87 |
| 4.2.5 Endpoint Thioflavin T assay and Thioflavin T kinetics | 88 |
| 4.2.6 Light scattering by protein aggregates | 89 |
| 4.2.7 Atomic Force Microscopy (AFM) | 89 |
| 4.2.8 Statistical analyses using OriginPro (Learning Edition) | 90 |
| 4.3 Results: | 90 |
| 4.3.1 Selected Intracellular metabolites enhance the amyloid formation of HEWL | 90 |
| 4.3.2 Atomic Force Microscopy imaging | 91 |
| 4.3.3 Light Scattering via UV and Turbidity assay | 91 |
| 4.3.4 Selected Intracellular metabolites quench tryptophan fluorescence of HEWL | 93 |
| 4.3.5 HEWL shows a saturating elongation and fragmentation-dominated aggregation pathway at physiological pH | 94 |
| 4.3.6 ThT Kinetic Analysis | 97 |
| 4.4 Discussion | 99 |
| 4.5 Conclusion | 102 |
| CHAPTER 5 | 104 |
| POTENTIAL ALTERNATIVES TO CURRENT CHOLINESTERASE INHIBITORS: AN <i>IN-SILICO</i> DRUG REPURPOSING APPROACH* | 104 |
| Abstract | 104 |

| | |
|--|------------|
| 5.1 Introduction | 105 |
| 5.2 Methodology | 108 |
| 5.2.1 Protein Preparation: | 108 |
| 5.2.2 Target Site Identification for Molecular Docking | 109 |
| 5.2.3 Selection and Preparation of Ligands | 110 |
| 5.2.4 Compound Screening and Molecular Docking | 111 |
| 5.2.5 Molecular Dynamic Simulation Studies | 111 |
| 5.2.6-MM/PBSA Free Energy Analysis | 112 |
| 5.2.7-Visual analysis | 112 |
| 5.2.8-ADME and Toxicity analyses | 113 |
| 5.3-Results | 113 |
| 5.3.1-Docking results with Acetylcholinesterase of Homo sapiens | 113 |
| 5.3.2 Docking results with Butyrylcholinesterase of Homo sapiens | 116 |
| 5.3.3 Molecular Simulation Results | 118 |
| 5.3.3.1 Simulation of Acetylcholinesterase | 119 |
| 5.3.2.2 Simulation of Butyrylcholinesterase | 120 |
| 5.3.4 ADME analysis results | 122 |
| 5.4 Discussion | 123 |
| 5.5 Conclusion | 125 |
| CHAPTER 6 | 126 |
| CONCLUSION & FUTURE SCOPE | 126-132 |
| REFERENCES | 133-143 |
| APPENDIX A | 144 |
| LIST OF PUBLICATIONS FROM THESIS WORK | 144 |
| APPENDIX B | 145 |
| CONFERENCES & WORKSHOPS | 145 |

List of Abbreviations

| | |
|-------|--|
| AchE | Acetylcholinesterase |
| AD | Alzheimer's Disease |
| ADME | Absorption Distribution Metabolism Excretion |
| AFM | Atomic Force Microscopy |
| ANS | 8-Anilino-naphthalene-1-sulfonic acid |
| ATP | Adenosine triphosphate |
| A1R | Adenosine 1 Receptor |
| A2R | Adenosine 2 Receptor |
| BuChE | Butyrylcholinesterase |
| CT | Computed Tomography |
| CTF | C-terminal Fragment |
| CTP | Cytidine Triphosphate |
| DLS | Dynamic Light Scattering |
| DNA | Deoxyribonucleic Acid |
| dNTP | deoxynucleotide triphosphates |
| DTT | Dithiothreitol |
| DMT | Disease Modifying Therapies |
| ER | Endoplasmic Reticulum |
| EM | Electron Microscopy |
| GPB | Guanine Based Purines |

| | |
|----------------|-------------------------------------|
| HD | Huntington's Disease |
| HEWL | Hen Egg White Lysozyme |
| LGA | Lamarckian Genetic Algorithm |
| MDS | Molecular Dynamics and Simulation |
| NMR | Nuclear Magnetic Resonance |
| NPT | Number Pressure Temperature |
| NVT | Number Volume Temperature |
| PD | Parkinson's Disease |
| PDB | Protein Data Bank |
| PET | Positron Emission Tomography |
| PLIP | Protein Ligand Interaction Profiler |
| PME | Particle Mesh Ewald |
| R _g | Radius of Gyration |
| RMSD | Root Mean Square Deviation |
| RMSF | Root Mean Square Fluctuation |
| RNA | Ribonucleic Acid |
| SASA | Solvent Accessible Surface Area |
| ThT | Thioflavin T |
| TTP | Thymidine Triphosphate |
| UV | Ultraviolet |
| UTP | Uridine Triphosphate |
| VDW | Van Der Waals |
| XRD | X-Ray Diffraction |

List of Tables

- Table 1.1-** Amyloid diseases affecting the nervous system of the patients and causing neurodegenerative conditions
- Table 1.2-** Non-neuropathic systematic amyloidosis conditions occurring in humans, their associated protein structural details
- Table 1.3-** Defective mutations associated with various genes in pyrimidine metabolism and their relative conditions
- Table 1.4-** Purine and Pyrimidine based drug development and their results in some neurological conditions
- Table 2.1-** Aggregation prone regions in hen egg-white lysozyme, their amino acid composition and grid coordinates for docking
- Table 2.2-** Details of various interactions between the amino acids and ligand when grid box no. 1 (25-32: LGNWVCAA) of HEWL. Detailed interaction of top 5 ligands based on binding energy is also given. N/A applies Not Applicable.
- Table 2.3-** Details of various interactions between the amino acids and ligand when grid box no. 2 (53-61: YGILQINSR) of HEWL. Detailed interaction of top 5 ligands based on binding energy is also given. N/A applies Not Applicable.
- Table 2.4-** Details of various interactions between the amino acids and ligand when grid box no. 3 (80-92: CSALLSSDITASV) of HEWL was fixed for the docking. Detailed interaction of top 5 ligands based on binding energy is also given. N/A applies Not Applicable.
- Table 2.5-** Details of various interactions between the amino acids and ligand when grid box no. 4 (105-110: MNAWVA) of HEWL was fixed for the docking. Detailed interaction of top 5 ligands based on binding energy is also given. N/A applies Not Applicable.
- Table 2.6-** Details of various interactions between the amino acids and ligand when grid box no.5 (120-124: VQAWI) of HEWL was fixed for the docking. Detailed interaction of top 5 ligands based on binding energy is also given. N/A applies Not Applicable.
- Table 2.7-** Details of various interactions between the amino acids and ligand when grid box no. 1 (15-20: QKLVFFA) of Amyloid β peptide was fixed for the docking. Detailed interaction of top 5 ligands based on binding energy is also given. N/A applies Not Applicable.
- Table 2.8-** Details of various interactions between the amino acids and ligand when grid box no. 2 (30-42: IIGLMVGGVVIA) of Amyloid β peptide was fixed for the docking. Detailed interaction of top 5 ligands based on binding energy is also given. N/A applies Not Applicable.
- Table 2.9-** Lipinski's parameters for drug likeliness and ADMET properties of chosen ligands and the approved standard drugs. Log P value represents the lipophilicity of the molecule, Log S value represents the water solubility, TPSA is Total Polar Solvent Accessibility, and BA is the oral bioavailability of a drug
- Table 3.1-** ThT Kinetics profiling of HEWL at 20 and 100 μ M concentration at pH 7.4 and pH 12.2

- Table 3.2-** Dynamic Light Scattering analysis of physiological and alkaline pH HEWL aggregates with and without ligands
- Table 3.3-** Computed solvent-accessible surface areas of the HEWL and the HEWL-metabolites complexes
- Table 3.4-** Details of Secondary structure of apoprotein and holoprotein complexes computed using DSSP tool
- Table 3.5-** MM/PBSA binding free energy analyses of the various ligands with hen egg-white lysozyme
- Table 4.1-** The approximate number of binding sites and Stern-Volmer Coefficient (K_{SV}) of the various ligands in the current study
- Table 4.2-** The combined $k_n k_+$ rates for various systems under consideration and the potential mode of action of various ligands in the study, n_c is 2.0 used as a global constant for nucleus size, $t_{1/2}$ is the time in which half of the maximum intensity is reached
- Table 4.3-** The approximate lag time in hours and potential mechanism of ligands in seeded reaction
- Table 5.1-** Small molecule drugs used in the current study, their usage and year of approval by the FDA
- Table 5.2-** Details of the proteins used for docking, the sites of docking and their respective coordinates and references
- Table 5.3-** Details of various ligand interactions, respective binding and intermolecular energy and inhibitor constant in Acetylcholinesterase from *Homo sapiens* (*HsAChE*). Donepezil is the positive control which is already an approved acetylcholinesterase inhibitor by FDA.
- Table 5.4-** Details of various ligand interactions, respective binding and intermolecular energy and inhibitor constant in Butyrylcholinesterase from *Homo sapiens* (*HsBuChE*). Donepezil is the positive control which is already an approved acetylcholinesterase inhibitor by FDA. VDW is Van Der Waal's interactions.
- Table 5.5-** MM/PBSA free energy analysis of Donepezil, Brexipiprazole and Pimavanserin in complex with butyrylcholinesterase, SASA is Surface Accessible Surface Area.
- Table 5.6-** MM/PBSA free energy analysis of Donepezil, Brexipiprazole and Sisonimod in complex with acetylcholinesterase, SASA is Surface Accessible Surface Area
- Table 5.7-** ADMET analysis of top 5 drugs across both the proteins taken in this study. We analysed the drugs for their drug likeliness and the following Lipinski's rule and its various parameters

List of Figures

- Fig 1.1:** Representations of different models to explain the protein folding process
- Fig 1.2-** Alois Alzheimer and his patient, Auguste Deter, the first person reported to have died from Alzheimer's disease (AD)
- Fig 1.3-** The various stages in the protein folding pathway
- Fig 1.4-** Diagrammatic representation of the protein folding process, the polypeptide's various intermediate states can form and take up during the folding process.
- Fig 1.5-** Classical sigmoidal kinetics, which is typical of the protein aggregation process.
- Fig 1.6-** Diagram showing two proteolytic pathways of the amyloidogenic precursor protein
- Fig 1.7-** Illustration of the de novo pathway highlights the incorporation of nucleoside triphosphates (NTPs) and dNTPs in RNA and DNA.
- Fig 1.8-** A Graphical representation of the action of pyrimidines and their role in improving cognitive functions and memory in the case of neurodegeneration.
- Fig 1.9-** A general illustration of the central hypothesis of the present study.
- Fig 1.10:** Model proteins visualised in Pymol used in this study
- Fig 2.1:** Ligplot images showing both hydrogen and hydrophobic interactions by (A) Guanine and (B) GMP with aggregation-prone sites of hen egg-white lysozyme.
- Fig 2.2:** Ligplot images showing both hydrogen and hydrophobic interactions by (A) Thymine and (B) GMP with second aggregation-prone sites of hen egg-white lysozyme.
- Fig 2.3:** Ligplot images showing both hydrogen and hydrophobic interactions by (A) Coumarin and (B) Guanine with third aggregation-prone sites of hen egg-white lysozyme.
- Fig 2.4:** Ligplot images showing both hydrogen and hydrophobic interactions by (A) GMP and (B) Guanine with aggregation-prone sites of hen egg-white lysozyme.
- Fig 2.5:** Ligplot images showing both hydrogen and hydrophobic interactions by (A) Guanine and (B) UMP with first aggregation-prone sites of amyloid β peptide.
- Fig 2.6:** Ligplot images showing both hydrogen and hydrophobic interactions by (A) Guanine and (B) UMP with aggregation-prone sites of amyloid β peptide.
- Fig 3.1-** Hen egg-white lysozyme aggregation trends at different time points
- Fig 3.2-** Thioflavin T and ANS intensity of 50 μ M HEWL samples incubated with selected nitrogenous bases and nucleosides at pH 7.4.
- Fig 3.3-** Thioflavin T and ANS intensity of 50 μ M HEWL samples incubated with selected nitrogenous bases and nucleosides at pH 12.2
- Fig 3.4-** Thioflavin T of HEWL samples incubated with various ligands at 1:10 concentration after 120 hours
- Fig 3.5-** Aggregation Index of HEWL incubated with bases and nucleosides at pH 7.4 and 12.2

- Fig 3.6-** Dynamic Light Scattering of Hen Egg White Lysozyme aggregates with and without ligands after 120 hours of incubation at **(A)** pH 7.4 and **(B)** pH 12.2.
- Fig 3.7-** AFM images of HEWL amyloid aggregates/fibrils in the absence and presence of ligands after 72 hours of incubation at pH 12.2
- Fig 3.8-** Histogram analysis of AFM images showing Heights Vs Counts of various systems in **(A)** pH 12.2 and **(B)** 7.4
- Fig 3.9-** Data from DispHscan Web server
- Fig 3.10-** Molecular Dynamics and simulation analyses of HEWL and HEWL-metabolites complexes for 100 ns run
- Fig 4.1-** Thioflavin T intensity after adding ligands to preformed HEWL oligomeric solutions. Thioflavin T intensity after **(A)** 0hr **(B)** 24hrs and **(C)** 72 hrs
- Fig 4.2-** Atomic Force Microscopy imaging of control sample and various other HEWL solutions in the presence of various ligands and **(B)** Histogram profiling showing the average heights and counts of the various samples
- Fig 4.3-** Turbidity of various performed HEWL early oligomeric solutions (120 hrs) after addition of ligands at different time points
- Fig 4.4-** Thioflavin T kinetics of HEWL at various concentrations
- Fig 4.5-** Tryptophan fluorescence quenching by various ligands
- Fig 4.6-** Thioflavin T Kinetics Analysis in **(A)** Unseeded HEWL oligomeric solutions and **(B)** Seeded HEWL oligomeric solutions with and without various ligands at desired concentrations.
- Fig 5.1-** Interaction of *Homo sapiens* Acetylcholinesterase (HuAChE) with **(A)** Deutetrabenazine and **(B)** Donepezil as seen in Discovery Studio Visualizer.
- Fig 5.2-** Interaction of *Homo sapiens* Butyrylcholinesterase (HuBChE) with **(A)** Brexipirazole and **(B)** Pimavansarin as seen in Discovery Studio Visualizer.
- Fig 5.3-** Molecular Dynamics and Simulation of AChE and BuChE **(A)** RMSD and **(B)** Radius of Gyration of AChE **(C)** RMSD and **(D)** Radius of gyration of BuChE **(E)** RMSF of Acetylcholinesterase and **(F)** RMSF of BuChE
- Fig 6.1-** The principle behind the potential binding of small molecules within disordered regions within the protein and their action of preventing further notorious interactions of the protein-based on which we performed our computational study
- Fig 6.2-** Protein aggregation phases
- Fig 6.3-** Possible mechanism of metabolites at various stages of HEWL aggregation.
- Fig 6.4-** 3D diagrams of interaction between FDA-approved drugs and critical enzymes in Alzheimer's Disease. The drugs could be potential cholinesterase inhibitors
- Fig 6.5-** Significant findings of the current study and future scope of research in bridging the connection between the role of intracellular metabolites and proteinopathies